Effects of interferon-alpha subtypes on the Th1/Th2 balance in peripheral blood mononuclear cells from patients with hepatitis virus infection-associated liver disorders

In Vitro Cellular and Developmental Biology - Animal

Volumn 41, Issue 1-2, 2005, Pages 50-56

  Ariyasu, Toshio ^a   Tanaka, Takeshi ^b   Fujioka, Noboru ^a   Yanai, Yoshiaki ^a   Yamamoto, Shigeto ^a   Yamauchi, Hiroshi ^a   Ikegami, Hakuo ^a   Ikeda, Masao ^a   Kurimoto, Masashi ^a  

^a HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Hepatitis; IFN subtype; Liver disorders; Th1 Th2 balance; Virus

Indexed keywords

ALPHA INTERFERON; ALPHA1 INTERFERON; ALPHA10 INTERFERON; ALPHA2 INTERFERON; ALPHA5 INTERFERON; ALPHA8 INTERFERON; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; TH1 CELL; TH2 CELL;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; FLOW CYTOMETRY; HEPATITIS, VIRAL, HUMAN; HUMANS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; LIVER DISEASES; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 20344397377     PISSN: 10712690     EISSN: None     Source Type: Journal    
DOI: 10.1290/0501008.1     Document Type: Article

References (53)

1. Agrati, C.; Nisii, C.; Oliva, A., et al. Lymphocyte distribution and intrahepatic compartmentalization during HCV infection: a main role for MHC-unrestricted T cells. Arch. Immunol. Ther. Exp. 50:307-316; 2002.
2. Ariyasu, T.; Fujioka, N.; Yamamoto, S., et al. Correlation between interferon alpha receptor protein expression and sensitivity to interferon alpha subtypes in human renal carcinoma cell lines. Cancer Genomics Proteomics 1:87-94; 2004.
3. Ariyasu, T.; Tanaka, T.; Fujioka, N., et al. In vitro modification of Th1/Th2 balance by interferon-alpha subtypes in peripheral blood mononuclear cells from patients with hepatitis B virus-infection. Biomed. Res. 24:231-237; 2003.
4. Cacciarelli, T. V.; Martinez, O. M.; Gish, R. G., et al. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and post-treatment with interferon alfa. Hepatology 24:6-9; 1996.
5. Calabrese, F.; Valente, M.; Giacometti, C., et al. Parenchymal transforming growth factor beta-1: its type II receptor and Smad signaling pathway correlate with inflammation and fibrosis in chronic liver disease of viral ethiology. J. Gastroenterol. Hepatol. 18:1302-1308; 2003.
6. Chau, G. Y.; Wu, C. W.; Lui, W. Y., et al. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann. Surg. 231:552-558; 2000.
7. Cook, J. R.; Cleary, C.; Izotova, L., et al. Ligand specific interactions of a splice variant form of the human interferon alpha receptor. J. Interferon Cytokine Res. 15:897; 1995.
8. De Maeyer, E.; De Maeyer-Guignard, J. Type I interferons. Int. Rev. Immunol. 17:53-73; 1998.
9. Diaz, M. O.; Bohlander, S.; Allen, G. Nomenclature of human interferon genes. J. Interferon Res. 13:243-244; 1993.
10. Fujioka, N.; Tanaka, T.; Ariyasu, T., et al. In vitro effects of interferon-alpha subtypes on the Th1/Th2 balance in the peripheral blood mononuclear cells from patients with hepatitis C virus infection. Biomed. Res. 25:75-82; 2004.
11. Herberman, R. B. Effect of alpha-interferons on immune function. Semin. Oncol. 24 (3 Suppl. 9):78-80; 1997.
12. Hoofnagle, J. H.; Mullen, K. D.; Jones, D. B., et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N. Engl. J. Med. 315:1575-1578; 1986.
13. Ikeda, K.; Saitoh, S.; Arase, Y., et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29:1124-1130; 1999.
14. Kakumu, S.; Ito, S.; Ishikawa, T., et al. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J. Gastroenterol. Hepatol. 15:431-436; 2000.
15. Kamal, S. M.; Graham, C. S.; He, Q., et al. Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and schistosoma mansoni coinfection: relation to progression of liver fibrosis. J. Infect. Dis. 189:1140-1150; 2004.
16. Kasahara, A.; Hayashi, N.; Mochizuki, K., et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka liver disease study group. Hepatology 27:1394-1402; 1998.
17. Kawakami, Y.; Nabeshima, S.; Furusyo, N., et al. Increased frequency of interferon-gamma-producing peripheral blood CD4+ T cells in chronic hepatitis C virus infection. Am. J. Gastroenterol. 95:227-232; 2000.
18. Kim, C. M.; Koike, K.; Saito, I., et al. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351:317-320; 1991.
19. Koziel, M. J. Cytokines in viral hepatitis. Semin. Liver Dis. 19:157-169; 1999.
20. Larrea, E.; Alberdi, A.; Castelruiz, Y., et al. Expression of interferon-α sub-types in peripheral mononuclear cells from patients with chronic hepatitis C: a role for interferon-α5. J. Viral Hepat. 8:103-110; 2001.
21. Lin, R.; Genin, P.; Mamane, Y., et al. Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of α/β interferon genes by interferon regulatory factors 3 and 7. Mol. Cell. Biol. 20:6342-6353; 2000.
22. Lohr, H. F.; Weber, W.; Schlaak, J., et al. Proliferative response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e-minus hepatitis B virus mutants. Hepatology 22:61-68; 1995.
23. Lutfalla, G.; Holland, S. J.; Cinalo, E., et al. Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J. 14:5100-5108; 1995.
24. Mailliard, R. B.; Son, Y. I.; Redlinger, R., et al. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J. Immunol. 171:2366-2373; 2003.
25. Marie, I.; Durbin, J. E.; Levy, D. E. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J. 17:6660-6669; 1998.
26. Martinez-Sierra, C.; Arizcorreta, A.; Diaz, F., et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin. Infect. Dis. 36:491-498; 2003.
27. Masaki, N.; Fukushima, S.; Hayashi, S. Lower th-1/th-2 ratio before interferon therapy may favor long-term virological responses in patients with chronic hepatitis C. Dig. Dis. Sci. 47:2163-2169; 2002.
28. Matikainen, S.; Paananen, A.; Miettinen, M., et al. IFN-alpha and IL-18 synergistically enhance IFN-gamma production in human NK cells: differential regulation of Stat4 activation and IFN-gamma gene expression by IFN-alpha and IL-12. Eur. J. Immunol. 31:2236-2245; 2001.
29. Moriya, K.; Fujie, H.; Shintani, Y., et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 4:1065-1067; 1998.
30. Mosmann, T. R.; Coffman, R. L. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173; 1989.
31. Mosmann, T. R.; Sad, S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17:138-146; 1996.
32. Nelson, D. R.; Lauwers, G. Y.; Lau, J. Y., et al. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 118:655-660; 2000.
33. Novick, D.; Cohen, B.; Rubinstein, M. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 77:391-400; 1994.
34. Okita, K.; Sakaida, I.; Hino, K. Current strategies for chemoprevention of hepatocellular carcinoma. Oncology 62:24-28; 2002.
35. Okuda, K. Hepatocellular carcinoma. J. Hepatol. 32:225-237; 2000.
36. Pawlotsky, J. M. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 12:96-102; 2004.
37. Pestka, S.; Langer, J. A.; Zoon, K. C., et al. Interferons and their actions. Annu. Rev. Biochem. 56:727-777; 1987.
38. Piazzolla, G.; Tortorella, C.; Fiore, G., et al. Interleukin-12 p40/p70 ratio and in vivo responsiveness to IFN-alpha treatment in chronic hepatitis C. J. Interferon Cytokine Res. 21:453-461; 2001.
39. Poynard, T.; Bedossa, P.; Opolon, P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349:825-832; 1997.
40. Rogge, L.; Barberis-Maino, L.; Biffi, M., et al. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J. Exp. Med. 185:825-831; 1997.
41. Rogge, L.; D'Ambrosio, D.; Biffi, M., et al. The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J. Immunol. 161:6567-6574; 1998.
42. Rossol, S.; Marinos, G.; Carucci, P., et al. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J. Clin. Invest. 99:3025-3033; 1997.
43. Sakaguchi, E.; Kayano, K.; Segawa, M., et al. Th1/Th2 imbalance in HCV-related liver cirrhosis [in Japanese]. Nippon Rinsho 59:1259-1263; 2001.
44. Schafer, D. F.; Sorrell, M. F. Hepatocellular carcinoma. Lancet 353:1253-1257; 1999.
45. Seder, R. A.; Paul, W. E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu. Rev. Immunol. 12:635-673; 1994.
46. Shirai, Y.; Kawata, S.; Tamura, S., et al. Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 73:2275-2279; 1994.
47. Sreenarasimhaiah, J.; Jaramillo, A.; Crippin, J., et al. Lack of optimal T-cell reactivity against the hepatitis C virus is associated with the development of fibrosis/cirrhosis during chronic hepatitis. Hum. Immunol. 64:224-230; 2003.
48. Szabo, E.; Paska, C.; Kaposi Novak, P., et al. Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis. Pathol. Oncol. Res. 10:5-11; 2004.
49. Uze, G.; Lutfalla, G.; Cresser, I. Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. Cell 60:225-234; 1990.
50. Yamamoto, S.; Yano, H.; Sanou, O., et al. Different antiviral activities of IFN-α subtypes in human liver cell lines: synergism between IFN-α2 and IFN-α8. Hepatol. Res. 24:99-106; 2002.
51. Yanai, Y.; Horie, S.; Yamamoto, K., et al. Characterization of the antitumor activities of IFN-α8 on renal cell carcinoma cells in vitro. J. Interferon Cytokine Res. 21:1129-1136; 2001a.
52. Yanai, Y.; Sanou, O.; Kayano, T., et al. Analysis of the antiviral activities of natural IFN-α preparations and their subtype compositions. J. Interferon Cytokine Res. 21:835-841; 2001b.
53. Yanai, Y.; Sanou, O.; Yamamoto, K., et al. The anti-tumor activities of interferon (IFN)-alpha in chronic myelogenous leukemia (CML)-derived cell lines depends on the IFN-alpha subtypes. Cancer Lett. 185:173-179; 2002.